203 reports of this reaction
2.3% of all CLOMIPRAMINE HYDROCHLORIDE reports
#2 most reported adverse reaction
SOMNOLENCE is the #2 most commonly reported adverse reaction for CLOMIPRAMINE HYDROCHLORIDE, manufactured by SpecGx LLC. There are 203 FDA adverse event reports linking CLOMIPRAMINE HYDROCHLORIDE to SOMNOLENCE. This represents approximately 2.3% of all 8,892 adverse event reports for this drug.
Patients taking CLOMIPRAMINE HYDROCHLORIDE who experience somnolence should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SOMNOLENCE is a less commonly reported adverse event for CLOMIPRAMINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to somnolence, the following adverse reactions have been reported for CLOMIPRAMINE HYDROCHLORIDE:
The following drugs have also been linked to somnolence in FDA adverse event reports:
SOMNOLENCE has been reported as an adverse event in 203 FDA reports for CLOMIPRAMINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
SOMNOLENCE accounts for approximately 2.3% of all adverse event reports for CLOMIPRAMINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience somnolence while taking CLOMIPRAMINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.